PRM134 - USING ADJUSTED INDIRECT COMPARISON IN HTA TO OVERCOME SHORT FOLLOW-UP TIME IN REGULATORY RANDOMIZED CONTROLED CLINICAL TRIALS- RIBOCICLIB AS FIRST-LINE THERAPY FOR HR-POSITIVE, ADVANCED BREAST CANCER
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2254
https://www.valueinhealthjournal.com/article/S1098-3015(18)35556-6/fulltext
Section Title :
Section Order :
1609
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35556-6&doi=10.1016/j.jval.2018.09.2254